Antimicrobial Drug/Test Joint Development Needs Better Incentives
Stakeholders still need to develop solutions that will allow faster development of susceptibility testing devices, and in turn facilitate prescribing of new antimicrobial drugs.
You may also be interested in...
Economic ‘pull’ incentives that don’t require direct government spending draw support from industry and academic stakeholders.
FDA and industry are turning their attention to implementation of the Generating Antibiotic Incentives Now provisions of PDUFA V, which include an additional five years of marketing exclusivity for certain products and new guidance aimed at streamlining the drug development process.
After US FDA's Oncologic Drugs Advisory Committee voted to delay approval of Karyopharm's multiple myeloma drug Xpovio, the company submitted some data from the Phase III BOSTON trial, which prompted the FDA to award an accelerated approval for a narrower indication.